Page last updated: 2024-09-04

lubiprostone and Hematochezia

lubiprostone has been researched along with Hematochezia in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Amagase, K; Hayashi, S; Kurata, N; Takeuchi, K; Yamaguchi, A	1

Other Studies

1 other study(ies) available for lubiprostone and Hematochezia

Article	Year
Lubiprostone prevents nonsteroidal anti-inflammatory drug-induced small intestinal damage by suppressing the expression of inflammatory mediators via EP4 receptors. The Journal of pharmacology and experimental therapeutics, 2014, Volume: 349, Issue:3 Topics: Alprostadil; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Cystic Fibrosis Transmembrane Conductance Regulator; Gastrointestinal Hemorrhage; Gastrointestinal Motility; Intestinal Mucosa; Intestine, Small; Lubiprostone; Male; Naphthalenes; Nitric Oxide Synthase Type II; Phenylbutyrates; Rats; Rats, Sprague-Dawley; Receptors, Prostaglandin E, EP4 Subtype; Tumor Necrosis Factor-alpha	2014

Article

Year

Lubiprostone prevents nonsteroidal anti-inflammatory drug-induced small intestinal damage by suppressing the expression of inflammatory mediators via EP4 receptors.

The Journal of pharmacology and experimental therapeutics, 2014, Volume: 349, Issue:3

Topics: Alprostadil; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Cystic Fibrosis Transmembrane Conductance Regulator; Gastrointestinal Hemorrhage; Gastrointestinal Motility; Intestinal Mucosa; Intestine, Small; Lubiprostone; Male; Naphthalenes; Nitric Oxide Synthase Type II; Phenylbutyrates; Rats; Rats, Sprague-Dawley; Receptors, Prostaglandin E, EP4 Subtype; Tumor Necrosis Factor-alpha

2014